Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Business Strategies Leadership Metabolic Disorders

Refocused Novo Nordisk Says On 'Road To Recovery' After Traumatic 2016

Executive Summary

Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now on the road to recovery.

You may also be interested in...



Clustering Of Diabetes Subgroups May Aid Outcome Predicting

This year's EASD meeting in Lisbon heard calls to re-categorize type 2 diabetes into novel subsets, as data suggest the approach could lead to better targeted treatments.

Diabetes-CV Disease Link Boosts EASD Buzz

Linkage between cardiovascular disease and type 2 diabetes was a top theme of discussion and data presented at this year's EASD meeting in Portugal's capital.

Novo Nordisk Settles Over US Federal Investigation Of Marketing Practices

Novo Nordisk has settled with the US Federal government over claims it did not comply with communicating safety information on its diabetes drug Victoza.

Table

View full table

Topics

Related Companies

Tags:
Business Strategies Leadership Metabolic Disorders
Latest Headlines

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

Normality Reasserts Itself For Biotech IPOs

See All
UsernamePublicRestriction

Register

SC099523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By